Warsaw

• A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic effects of Subcutaneous Ocrelizumab in Childr … Pending
  2025-524164-37-00 4 Relapsing-Remitting Multiple Sclerosis (RRMS)
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant … Pending
  2025-524241-27-00 5 Treatment-naїve mantle cell lymphoma (MCL)
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending
  2025-524623-50-00 9 Solid Tumors
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 4 Ulcerative colitis (Inflammatory Bowel Disease)
• Phase IV VR in relapsed CLL – Polish experience Pending
  2025-524795-35-00 6 Adult with chronic lymphocytic leukemia/small lymphocytic lymphoma (CL
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease. Pending
  2025-524855-30-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P … Pending
  2025-525009-18-00 5 Pancreatic Ductal Adenocarcinoma
• Clinical trial (study) comparing the efficacy and safety of mifamurtide versus standard treatment containing sorafenib in pediatric and youn … Pending
  2026-525223-24-00 4 Relapsed/refractory osteosarcoma, High-grade osteosarcoma
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 5 Hodgkin lymphoma
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting
  2025-522434-32-00 5 2026-07-01 Hemophilia A Without Inhibitors
• A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8 … Recruiting
  2025-524575-22-00 10 2026-06-30 Neovascular age-related macular degeneration (NVAMD)
• ​A study to evaluate safety and explore efficacy of new lipase NHS7108 compared with pancrelipase in adult participants with exocrine pancre … Recruiting
  2025-521816-20-00 4 2026-06-29 ​​Exocrine Pancreatic Insufficiency​
• A clinical trial of MK-8690 in people with ulcerative colitis (MK-8690-002) Recruiting
  2025-523479-49-00 4 2026-06-29 Colitis ulcerative
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis. Recruiting
  2025-523939-18-00 9 2026-06-23 Amyotrofic Lateral Sclerosis (ALS)
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Recruiting
  2025-523579-47-00 4 2026-06-19 moderate to severe rheumatoid arthritis (RA)
• A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Recruiting
  2024-516436-10-00 5 2026-06-18 Acute myeloid leukemia
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting
  2025-522435-33-00 5 2026-06-17 Hemophilia A
• A clinical trial of MK-1084 and durvalumab in people with non-small cell lung cancer (MK-1084-015) Recruiting
  2025-522038-29-00 5 2026-06-16 Locally advanced, unresected (unresectable or medically inoperable or
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr … Recruiting
  2025-522406-20-00 9 2026-06-15 Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

Showing 97–120 of 1,722 trials